View in EDS

In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.

Saved in:
Bibliographic Details
Title: In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Authors: Rifkin RM; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO 80218, USA., Costello CL; Department of Medicine, Division of Blood & Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Birhiray RE; Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN 46260, USA., Kambhampati S; Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA., Richter J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Abonour R; Indiana University School of Medicine, Indianapolis, IN 46202, USA., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Stokes M; Evidera, Data Analytics, St-Laurent, Quebec, H4T 1V6, Canada., Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA., Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Cherepanov D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA., Bogard K; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Noga SJ; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Girnius S; TriHealth Cancer Institute, Cincinnati, OH 45247, USA.
Source: Future oncology (London, England) [Future Oncol] 2024 Jan; Vol. 20 (3), pp. 131-143. Date of Electronic Publication: 2023 Oct 09.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37807952
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Rifkin+RM%22">Rifkin RM</searchLink>; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO 80218, USA.<br /><searchLink fieldCode="AU" term="%22Costello+CL%22">Costello CL</searchLink>; Department of Medicine, Division of Blood & Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA.<br /><searchLink fieldCode="AU" term="%22Birhiray+RE%22">Birhiray RE</searchLink>; Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN 46260, USA.<br /><searchLink fieldCode="AU" term="%22Kambhampati+S%22">Kambhampati S</searchLink>; Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA.<br /><searchLink fieldCode="AU" term="%22Richter+J%22">Richter J</searchLink>; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.<br /><searchLink fieldCode="AU" term="%22Abonour+R%22">Abonour R</searchLink>; Indiana University School of Medicine, Indianapolis, IN 46202, USA.<br /><searchLink fieldCode="AU" term="%22Lee+HC%22">Lee HC</searchLink>; M.D. Anderson Cancer Center, Houston, TX 77030, USA.<br /><searchLink fieldCode="AU" term="%22Stokes+M%22">Stokes M</searchLink>; Evidera, Data Analytics, St-Laurent, Quebec, H4T 1V6, Canada.<br /><searchLink fieldCode="AU" term="%22Ren+K%22">Ren K</searchLink>; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA.<br /><searchLink fieldCode="AU" term="%22Stull+DM%22">Stull DM</searchLink>; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA.<br /><searchLink fieldCode="AU" term="%22Cherepanov+D%22">Cherepanov D</searchLink>; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA.<br /><searchLink fieldCode="AU" term="%22Bogard+K%22">Bogard K</searchLink>; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA.<br /><searchLink fieldCode="AU" term="%22Noga+SJ%22">Noga SJ</searchLink>; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA.<br /><searchLink fieldCode="AU" term="%22Girnius+S%22">Girnius S</searchLink>; TriHealth Cancer Institute, Cincinnati, OH 45247, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2024 Jan; Vol. 20 (3), pp. 131-143. <i>Date of Electronic Publication: </i>2023 Oct 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37807952
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2217/fon-2023-0272
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 131
    Titles:
      – TitleFull: In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rifkin RM
      – PersonEntity:
          Name:
            NameFull: Costello CL
      – PersonEntity:
          Name:
            NameFull: Birhiray RE
      – PersonEntity:
          Name:
            NameFull: Kambhampati S
      – PersonEntity:
          Name:
            NameFull: Richter J
      – PersonEntity:
          Name:
            NameFull: Abonour R
      – PersonEntity:
          Name:
            NameFull: Lee HC
      – PersonEntity:
          Name:
            NameFull: Stokes M
      – PersonEntity:
          Name:
            NameFull: Ren K
      – PersonEntity:
          Name:
            NameFull: Stull DM
      – PersonEntity:
          Name:
            NameFull: Cherepanov D
      – PersonEntity:
          Name:
            NameFull: Bogard K
      – PersonEntity:
          Name:
            NameFull: Noga SJ
      – PersonEntity:
          Name:
            NameFull: Girnius S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2024 Jan
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1